Courtney Breen
Stock Analyst at Bernstein
(4.64)
# 864
Out of 5,020 analysts
309
Total ratings
91.1%
Success rate
21.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Courtney Breen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintained: Hold | $45 | $182.56 | -75.35% | 43 | Sep 25, 2026 | |
| PFE Pfizer | Maintained: Hold | $29 | $27.93 | +3.83% | 40 | Sep 23, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $160 | $152.67 | +4.80% | 31 | Sep 7, 2026 | |
| MRK Merck & Co. | Reiterated: Hold | $105 | $150.91 | -30.42% | 41 | Sep 7, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,385 | $1,170.14 | +18.36% | 62 | Aug 31, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | n/a | $62.25 | - | 32 | Aug 20, 2026 | |
| AMGN Amgen | Reiterated: Hold | $335 → $345 | $410.24 | -15.90% | 31 | Aug 5, 2026 | |
| ABBV AbbVie | Reiterated: Hold | $225 | $265.21 | -15.16% | 29 | Jul 22, 2026 |
Moderna
Sep 25, 2026
Maintained: Hold
Price Target: $45
Current: $182.56
Upside: -75.35%
Pfizer
Sep 23, 2026
Maintained: Hold
Price Target: $29
Current: $27.93
Upside: +3.83%
Gilead Sciences
Sep 7, 2026
Reiterated: Buy
Price Target: $160
Current: $152.67
Upside: +4.80%
Merck & Co.
Sep 7, 2026
Reiterated: Hold
Price Target: $105
Current: $150.91
Upside: -30.42%
Eli Lilly and Company
Aug 31, 2026
Reiterated: Buy
Price Target: $1,385
Current: $1,170.14
Upside: +18.36%
Bristol-Myers Squibb Company
Aug 20, 2026
Reiterated: Hold
Price Target: n/a
Current: $62.25
Upside: -
Amgen
Aug 5, 2026
Reiterated: Hold
Price Target: $335 → $345
Current: $410.24
Upside: -15.90%
AbbVie
Jul 22, 2026
Reiterated: Hold
Price Target: $225
Current: $265.21
Upside: -15.16%